Search Results - Eugene Balagula

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-Controlled Study (PSORIATYK SCALP)

    Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-R... by Linda Stein Gold, Michael Sebastian, Eugene Balagula, Brandon Becker, Yichen Zhong, Rachel Dyme, Michael DeRosa, Scott Fretzin, Andreas Pinter, C.E.M. Griffiths

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: